Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,437 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy.
Ströbele S, Schneider M, Schneele L, Siegelin MD, Nonnenmacher L, Zhou S, Karpel-Massler G, Westhoff MA, Halatsch ME, Debatin KM. Ströbele S, et al. Among authors: schneider m. PLoS One. 2015 Jun 29;10(6):e0131670. doi: 10.1371/journal.pone.0131670. eCollection 2015. PLoS One. 2015. PMID: 26121251 Free PMC article.
Inhibition of NF-κB signaling ablates the invasive phenotype of glioblastoma.
Westhoff MA, Zhou S, Nonnenmacher L, Karpel-Massler G, Jennewein C, Schneider M, Halatsch ME, Carragher NO, Baumann B, Krause A, Simmet T, Bachem MG, Wirtz CR, Debatin KM. Westhoff MA, et al. Among authors: schneider m. Mol Cancer Res. 2013 Dec;11(12):1611-23. doi: 10.1158/1541-7786.MCR-13-0435-T. Epub 2013 Oct 21. Mol Cancer Res. 2013. PMID: 24145173
A paired comparison between glioblastoma "stem cells" and differentiated cells.
Schneider M, Ströbele S, Nonnenmacher L, Siegelin MD, Tepper M, Stroh S, Hasslacher S, Enzenmüller S, Strauss G, Baumann B, Karpel-Massler G, Westhoff MA, Debatin KM, Halatsch ME. Schneider M, et al. Int J Cancer. 2016 Apr 1;138(7):1709-18. doi: 10.1002/ijc.29908. Epub 2015 Nov 17. Int J Cancer. 2016. PMID: 26519239
Inhibition of PI3K signalling increases the efficiency of radiotherapy in glioblastoma cells.
Hasslacher S, Schneele L, Stroh S, Langhans J, Zeiler K, Kattner P, Karpel-Massler G, Siegelin MD, Schneider M, Zhou S, Grunert M, Halatsch ME, Nonnenmacher L, Debatin KM, Westhoff MA. Hasslacher S, et al. Among authors: schneider m. Int J Oncol. 2018 Nov;53(5):1881-1896. doi: 10.3892/ijo.2018.4528. Epub 2018 Aug 16. Int J Oncol. 2018. PMID: 30132519 Free PMC article.
Inhibition of Gap Junctions Sensitizes Primary Glioblastoma Cells for Temozolomide.
Potthoff AL, Heiland DH, Evert BO, Almeida FR, Behringer SP, Dolf A, Güresir Á, Güresir E, Joseph K, Pietsch T, Schuss P, Herrlinger U, Westhoff MA, Vatter H, Waha A, Schneider M. Potthoff AL, et al. Among authors: schneider m. Cancers (Basel). 2019 Jun 20;11(6):858. doi: 10.3390/cancers11060858. Cancers (Basel). 2019. PMID: 31226836 Free PMC article.
Inhibition of Intercellular Cytosolic Traffic via Gap Junctions Reinforces Lomustine-Induced Toxicity in Glioblastoma Independent of MGMT Promoter Methylation Status.
Schneider M, Potthoff AL, Evert BO, Dicks M, Ehrentraut D, Dolf A, Schmidt ENC, Schäfer N, Borger V, Pietsch T, Westhoff MA, Güresir E, Waha A, Vatter H, Heiland DH, Schuss P, Herrlinger U. Schneider M, et al. Pharmaceuticals (Basel). 2021 Feb 27;14(3):195. doi: 10.3390/ph14030195. Pharmaceuticals (Basel). 2021. PMID: 33673490 Free PMC article.
Meclofenamate causes loss of cellular tethering and decoupling of functional networks in glioblastoma.
Schneider M, Vollmer L, Potthoff AL, Ravi VM, Evert BO, Rahman MA, Sarowar S, Kueckelhaus J, Will P, Zurhorst D, Joseph K, Maier JP, Neidert N, d'Errico P, Meyer-Luehmann M, Hofmann UG, Dolf A, Salomoni P, Güresir E, Enger PØ, Chekenya M, Pietsch T, Schuss P, Schnell O, Westhoff MA, Beck J, Vatter H, Waha A, Herrlinger U, Heiland DH. Schneider M, et al. Neuro Oncol. 2021 Nov 2;23(11):1885-1897. doi: 10.1093/neuonc/noab092. Neuro Oncol. 2021. PMID: 33864086 Free PMC article.
Tonabersat enhances temozolomide-mediated cytotoxicity in glioblastoma by disrupting intercellular connectivity through connexin 43 inhibition.
Schmidt ENC, Evert BO, Pregler BEF, Melhem A, Hsieh MC, Raspe M, Strobel H, Roos J, Pietsch T, Schuss P, Fischer-Posovszky P, Westhoff MA, Hölzel M, Herrlinger U, Vatter H, Waha A, Schneider M, Potthoff AL. Schmidt ENC, et al. Among authors: schneider m. Mol Oncol. 2024 Dec 16. doi: 10.1002/1878-0261.13786. Online ahead of print. Mol Oncol. 2024. PMID: 39680504 Free article.
Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy-the MecMeth/NOA-24 trial.
Zeyen T, Potthoff AL, Nemeth R, Heiland DH, Burger MC, Steinbach JP, Hau P, Tabatabai G, Glas M, Schlegel U, Grauer O, Krex D, Schnell O, Goldbrunner R, Sabel M, Thon N, Delev D, Clusmann H, Seidel C, Güresir E, Schmid M, Schuss P, Giordano FA, Radbruch A, Becker A, Weller J, Schaub C, Vatter H, Schilling J, Winkler F, Herrlinger U, Schneider M. Zeyen T, et al. Among authors: schneider m. Trials. 2022 Jan 19;23(1):57. doi: 10.1186/s13063-021-05977-0. Trials. 2022. PMID: 35045869 Free PMC article. Clinical Trial.
7,437 results